Biora Therapeutics, Inc. (NASDAQ:BIOR) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET

Company Participants

Chuck Padala - Managing Director, LifeSci Advisors
Adi Mohanty - Chief Executive Officer
Eric d'Esparbes - Chief Financial Officer

Conference Call Participants

Joseph Pantginis - H.C. Wainwright
Rei Tan - BTIG
John Vandermosten - Zacks

Operator

Greetings and welcome to Biora Therapeutics First Quarter 2024 Financial Results Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a remainder, this conference is being recorded.

I will now turn the call over to Chuck Padala, Managing Director with LifeSci Advisors, Biora's Investor Relations firm. Please go ahead.

Chuck Padala

Thank you, operator. Good afternoon and welcome to the Biora Therapeutics First Quarter 2024 Corporate Update and Financial Results Conference Call. Joining me on the call are Adi Mohanty, Chief Executive Officer; and Eric d'Esparbes, Chief Financial Officer.

Before I turn the call over to Mr. Mohanty, I would like to remind you that today's call will include forward-looking statements within the meaning of the federal securities laws, including, but not limited to, the types of statements identified as forward-looking in our quarterly report on Form 10-Q that we filed or will file later today and our subsequent reports filed with the SEC, which are available on our website in the Investors section.

These forward-looking statements represent our views only as of the date of this call and involve substantial risks and uncertainties, including many that are beyond our control. Please note that the actual results could differ materially from those expressed in the forward-looking statements.

For a further description of the risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements as well as risks related to our business, please see the company's periodic reports filed with the SEC.

With that, I will now turn the call over to Adi Mohanty, CEO of Biora Therapeutics. Adi?

Adi Mohanty

Thanks, Chuck, and thank you, everyone, for joining us. In the short few weeks since our last corporate update, we had excellent progress in the execution of our clinical development plans for the NaviCap platform, successfully completing dosing of our clinical study of BT-600.

For the BioJet platform, we have continued to advance our goals for both platform development and business development with pharma. First, an update on our NaviCap targeted therapeutics platform with our lead program, BT-600 in ulcerative colitis.